CR9577A - Formulaciones farmaceuticas de liberacion inmediata y con una carga de droga elevada de (4-clorofenil) - Google Patents

Formulaciones farmaceuticas de liberacion inmediata y con una carga de droga elevada de (4-clorofenil)

Info

Publication number
CR9577A
CR9577A CR9577A CR9577A CR9577A CR 9577 A CR9577 A CR 9577A CR 9577 A CR9577 A CR 9577A CR 9577 A CR9577 A CR 9577A CR 9577 A CR9577 A CR 9577A
Authority
CR
Costa Rica
Prior art keywords
chlorophenyl
immediate release
pharmaceutical formulations
load
high drug
Prior art date
Application number
CR9577A
Other languages
English (en)
Inventor
Thomas Backensfeld
Torsten Wagner
Kai Juergens
Adrian Funke
Kai Thode
Heiko Kranz
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of CR9577A publication Critical patent/CR9577A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Formulaciones farmaceuticas solidas de liberacion inmediata y con una carga de droga elevada que comprenden (4-clorofenil)[4-(piridilmetil)-ftalazin-1-ilo] micronizado, asi como sus sales aceptables para uso farmaceutico.
CR9577A 2005-06-07 2007-12-07 Formulaciones farmaceuticas de liberacion inmediata y con una carga de droga elevada de (4-clorofenil) CR9577A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05090167A EP1731154A1 (en) 2005-06-07 2005-06-07 Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl)|4-(4-pyridylmethyl)pht halazin-1-yl| and salts thereof

Publications (1)

Publication Number Publication Date
CR9577A true CR9577A (es) 2008-03-06

Family

ID=34938468

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9577A CR9577A (es) 2005-06-07 2007-12-07 Formulaciones farmaceuticas de liberacion inmediata y con una carga de droga elevada de (4-clorofenil)

Country Status (22)

Country Link
EP (2) EP1731154A1 (es)
JP (1) JP2008542421A (es)
KR (1) KR20080017443A (es)
CN (1) CN101242841A (es)
AR (1) AR054377A1 (es)
AU (1) AU2006256853A1 (es)
BR (1) BRPI0611818A2 (es)
CA (1) CA2610977A1 (es)
CR (1) CR9577A (es)
CU (1) CU20070272A7 (es)
DO (1) DOP2006000128A (es)
EC (1) ECSP078037A (es)
GT (1) GT200600243A (es)
IL (1) IL187906A0 (es)
MX (1) MX2007015495A (es)
NO (1) NO20080066L (es)
PE (1) PE20070012A1 (es)
RU (1) RU2007147953A (es)
TW (1) TW200716114A (es)
UY (1) UY29585A1 (es)
WO (1) WO2006131394A1 (es)
ZA (1) ZA200800113B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1958616A1 (en) * 2007-02-13 2008-08-20 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical formulations of 1-[4-chloroanilino]-4-[4-pyridylmethyl] phthalazine or salts thereof
EP1958615A1 (en) * 2007-02-13 2008-08-20 Bayer Schering Pharma Aktiengesellschaft Solid pharmaceutical formulations of a homogeneous dispersion of active principles having pH-dependent solubility
WO2016020901A1 (en) 2014-08-07 2016-02-11 Acerta Pharma B.V. Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of proton tyrosine kinase inhibitor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
AU3980499A (en) 1998-05-11 1999-11-29 Endowment for Research in Human Biology, Inc., The Use of neomycin for treating angiogenesis-related diseases

Also Published As

Publication number Publication date
JP2008542421A (ja) 2008-11-27
RU2007147953A (ru) 2009-07-20
GT200600243A (es) 2007-07-16
ECSP078037A (es) 2008-01-23
EP1888073A1 (en) 2008-02-20
CN101242841A (zh) 2008-08-13
TW200716114A (en) 2007-05-01
DOP2006000128A (es) 2006-12-15
PE20070012A1 (es) 2007-02-07
AR054377A1 (es) 2007-06-20
CU20070272A7 (es) 2010-09-30
WO2006131394A1 (en) 2006-12-14
ZA200800113B (en) 2009-07-29
UY29585A1 (es) 2007-01-31
EP1731154A1 (en) 2006-12-13
NO20080066L (no) 2008-03-06
KR20080017443A (ko) 2008-02-26
IL187906A0 (en) 2008-03-20
BRPI0611818A2 (pt) 2010-09-28
CA2610977A1 (en) 2006-12-14
MX2007015495A (es) 2008-02-22
AU2006256853A1 (en) 2006-12-14

Similar Documents

Publication Publication Date Title
CR20110110A (es) Composicion farmaceutica
ECSP088680A (es) Arildihidroisoquinolinonas sustituidas con azaciclilo, procedimiento para su preparación y su uso como medicamentos
NO20080220L (no) Formuleringer med hoy medikament belastning og doseringsformer
CL2008002051A1 (es) Compuestos derivados de isoxazol-4-metoxi, triazol-4-metoxi o pirazol-4-metoxi, con actividad agonista del receptor x de farnesoide (fxr); composicion farmaceutica que los contiene; y el uso de los compuestos en la preparacion de medicamentos utiles para el tratamiento de dislipidemia y enfermedades relacionadas.
UY30163A1 (es) Nuevas ariltienopirimidinonas sustituidas con azaciclilo, procedimiento para su preparación y su uso como medicamentos
MX2009010289A (es) Composiciones para administracion nasal.
UY31456A1 (es) Derivados de 2-pirazinona como inhibidores de la elastasa de los neutrofilos
ECSP077243A (es) Formulación de pelet de liberación extendida que contiene pramipexol o una de sus sales farmacéuticamente aceptable, un método para su fabricación y su uso
UY32203A (es) Amino pirimidinas y su uso en terapia
CR10573A (es) Derivados del pirazol como inhibidores del citocromo p450
UY33201A (es) Compuestos de pirazol como antagonistas de crth2.
ECSP088296A (es) Compuestos terapéuticos
UY29562A1 (es) Compuestos heterocíclicos de amino benzoilo, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
AR061348A1 (es) Preparados estables de laquinimod
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
FR2949062B1 (fr) Nouvelles formulations pharmaceutiques contre le mesusage des medicaments
UY30165A1 (es) Nuevas arildihidroisoquinolinonas sustituidas con aminolcoholes, procedimiento para su preparación y su uso como medicamentos
MX2010004222A (es) Formulaciones solidas de compuestos cristalinos.
UY29561A1 (es) Derivados de quinazolina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
SV2009003366A (es) Estabilizacion de vitamina b12
AR082493A1 (es) Formulaciones a base de nalbufina, y sus utilizaciones
UY31788A (es) Formulación farmacéutica sólida con liberación retardada
UY29701A1 (es) Formulaciones líquidas para la administración controlada de derivados de bencisoxazol
ECSP13012832A (es) Compuestos de pirazol como antagonistas de crth2
ECSP078037A (es) Formulaciones farmacéuticas de liberación inmediata y con una carga de droga elevada de (4-clorofenil)[4-(4-piridilmetil)ftalazin-1-ilo] micronizado, y sus sales

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)